Stockreport

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 [Yahoo! Fi...

InspireMD Inc.  (NSPR) 
NASDAQ:AMEX Investor Relations: inspiremd.com/en/investors/investor-relations
PDF System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid [Read more]